Department of Respiratory Medicine, Maastricht UMC+, Maastricht, the Netherlands.
UCL Respiratory, University College London, London, UK.
Expert Rev Cardiovasc Ther. 2024 Apr-May;22(4-5):177-191. doi: 10.1080/14779072.2024.2333786. Epub 2024 Mar 27.
Chronic Obstructive Pulmonary Disease (COPD) and cardiovascular diseases (CVD) commonly co-exist. Outcomes of people living with both conditions are poor in terms of symptom burden, receiving evidence-based treatment and mortality. Increased understanding of the underlying mechanisms may help to identify treatments to relieve this disease burden. This narrative review covers the overlap of COPD and CVD with a focus on clinical presentation, mechanisms, and interventions. Literature up to December 2023 are cited.
The prospective identification of co-morbid COPD in CVD patients and of CVD and CV risk in people with COPD is crucial for optimizing clinical outcomes. This includes the identification of novel treatment targets and the design of clinical trials specifically designed to reduce the cardiovascular burden and mortality associated with COPD. Databases searched: Pubmed, 2006-2023.
慢性阻塞性肺疾病(COPD)和心血管疾病(CVD)通常同时存在。患有这两种疾病的人的预后在症状负担、接受循证治疗和死亡率方面都较差。增加对潜在机制的理解可能有助于确定减轻这一疾病负担的治疗方法。本综述涵盖了 COPD 和 CVD 的重叠,重点介绍了临床表现、机制和干预措施。引用了截至 2023 年 12 月的文献。
在 CVD 患者中前瞻性识别合并 COPD,以及在 COPD 患者中识别 CVD 和 CV 风险,对于优化临床结局至关重要。这包括确定新的治疗靶点和专门设计的临床试验,以降低与 COPD 相关的心血管负担和死亡率。检索数据库:Pubmed,2006-2023 年。